



Nina Schooler

SUNY Downstate Health Sciences University

Bio:

Dr. Schooler is Professor of Psychiatry and Behavioral Sciences at State University of New York Downstate Health Sciences University, Brooklyn, NY. Her substantive research focuses on treatment of schizophrenia from its earliest identification to long term course and outcomes. She is also interested in methods for innovative clinical trial designs and development of assessment tools.

She is a fellow of the American College of Neuropsychopharmacology, the Collegium Internationale Neuropsychopharmacologicum (CINP), the American Psychological Association, and the Association for Psychological Science and a longtime member of Schizophrenia International Research Society (SIRS) and of the ISCTM. Dr. Schooler has been President of the American Psychopathological Association and the Association for Clinical Psychosocial Research, has served as an elected Councillor of the CINP. and of Executive Board of SIRS. She publishes widely in the peer-reviewed psychiatric literature and has served as an editor for volumes relating to psychiatric clinical trials, clinical assessment, and research methods.

Prof. Schooler's contributions to the field have been recognized by numerous awards; she was honored to be the first recipient of the Andrew Leon Lifetime Achievement Award from the ISCTM in 2012.

She received her PhD in Social Psychology from Columbia University in New York, and later served in leadership positions at the National Institute of Mental Health, Bethesda, Maryland, where she led a series of significant multicenter clinical trials of medication and psychosocial treatments for schizophrenia. She subsequently joined the Department of Psychiatry at the University of Pittsburgh, in Pennsylvania, where she directed the Psychosis Research Program and was Professor of Psychiatry and Psychology. She then served as Director of Psychiatry Research at the Zucker Hillside Hospital, conducting research in treatment of first-episode psychosis, negative symptoms and long-acting injectable antipsychotics in schizophrenia. Currently, her ongoing research focuses on multi-modal treatment approaches to first episode psychosis, treatment for patients later in the course of schizophrenia illnesses who are at high risk for rehospitalization and long-term medication treatment for schizophrenia. She is also involved in development of methods to improve clinical assessment and development of improved rating scales.